RA-9|cas:919091-63-7|西域试剂

RA-9,98.67%

产品编号：Bellancom-136528| CAS NO：919091-63-7| 分子式：C₁₉H₁₅N₃O₅| 分子量：365.34

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-136528	￥550.00	杭州北京（现货）
Bellancom-136528	￥950.00	杭州北京（现货）
Bellancom-136528	￥2400.00	杭州北京（现货）
Bellancom-136528	￥4200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

RA-9

产品介绍

RA-9 是一种高效选择性蛋白酶体相关 DUBs 抑制剂，具有良好的毒性和抗癌活性。RA-9 阻断泛素依赖性蛋白降解而不影响 20S 蛋白酶体蛋白水解活性。RA-9 选择性诱导卵巢癌细胞株和供体原代培养细胞凋亡。RA-9 诱导卵巢癌细胞内质网应激反应。

生物活性

RA-9 is a potent and selective proteasome-associated deubiquitinating enzymes (DUBs) inhibitor with favorable toxicity profile and anticancer activity. RA-9 blocks ubiquitin-dependent protein degradation without impacting 20S proteasome proteolytic activity. RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors. RA-9 induces endoplasmic reticulum (ER)-stress responses in ovarian cancer cells.

体外研究

RA-9 (10-30 μM; 48 hours) inhibits growth of ovarian cancer cell lines and primary cultures.
RA-9 (1.25-5 μM; 18 hours) causes cell cycle arrest and caspase-mediated apoptosis in ovarian cancer cells.
RA-9 (5 μM; 0-24 hours) induces ER-stress responses in ovarian cancer cells.
RA-9 (5 μM; over 24 hours) treatment results with time-dependent accumulation of the cleaved formed of PARP noticeable as early as 8 hours.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Cisplatin-sensitive ovarian cancer cell lines TOV-21G and ES-2, Cisplatin-resistant ovarian cancer cell lines HEY and OVCAR-3, primary ovarian cancer cells
Concentration:	10, 20, 30 μM
Incubation Time:	48 hours
Result:	Compromised the viability of ovarian cancer cells in a dose-dependent fashion.

Cell Cycle Analysis

Cell Line:	ES-2 cells
Concentration:	1.25, 5 μM
Incubation Time:	18 hours
Result:	Resulted in a dose-dependent increase in the fraction of ES-2 cells in the G2-M cell cycle phase.

Western Blot Analysis

Cell Line:	ES-2, SKOV-3 and TOV-21G ovarian cancer cells
Concentration:	5 μM
Incubation Time:	0-24 h
Result:	Caused a time-dependent increase in the steady levels of the early ER-stress marker GRP-78, as well as the late ER-stress markers IRE1-α and Ero1L-α.

体内研究
(In Vivo)

RA-9 (5 mg/kg; i.p; one-day on, two-days off) inhibits human ovarian cancer cell growth in vivo and prolongs survival in a mouse model for ovarian cancer.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female immunodeficient (NCr nu/nu) mice
Dosage:	5 mg/kg
Administration:	I.p; one-day on, two-days off
Result:	Significant reduction in tumor burden at day 12.

体内研究

RA-9 (5 mg/kg; i.p; one-day on, two-days off) inhibits human ovarian cancer cell growth in vivo and prolongs survival in a mouse model for ovarian cancer.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female immunodeficient (NCr nu/nu) mice
Dosage:	5 mg/kg
Administration:	I.p; one-day on, two-days off
Result:	Significant reduction in tumor burden at day 12.

体内研究

RA-9 (5 mg/kg; i.p; one-day on, two-days off) inhibits human ovarian cancer cell growth in vivo and prolongs survival in a mouse model for ovarian cancer.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Six-week-old female immunodeficient (NCr nu/nu) mice
Dosage:	5 mg/kg
Administration:	I.p; one-day on, two-days off
Result:	Significant reduction in tumor burden at day 12.

性状

Solid

溶解性数据

In Vitro:

DMSO : 4.17 mg/mL (11.41 mM; ultrasonic and warming and heat to 80°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7372 mL	13.6859 mL	27.3718 mL
5 mM	0.5474 mL	2.7372 mL	5.4744 mL
10 mM	0.2737 mL	1.3686 mL	2.7372 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式